Clinical factors influencing the efficacy of pooled platelet transfusions
- PMID: 3337903
Clinical factors influencing the efficacy of pooled platelet transfusions
Abstract
To determine the relative importance of clinical factors on the efficacy of platelet transfusions, 941 pooled platelet transfusions from HLA-unmatched donors were studied prospectively in 133 patients with bone marrow failure. Multiple linear regression analyses identified the major factors influencing one-hour-corrected increments (CI) as prior splenectomy, bone marrow transplantation, disseminated intravascular coagulation, concurrent intravenous amphotericin B, splenomegaly, and HLA antibody grade. The relative impact of these factors on CI has been quantitated by using a formula developed from these data. A linear relationship was demonstrated between increasing percentage of HLA antibody grade and decreasing CI. A number of other factors were less important in the linear regression model than the aforementioned major factors. These included platelet-specific antibodies, concurrent antibacterial antibiotics, clinical bleeding grade, and temperature. Factors that did not influence CI included the number of prior platelet transfusions, prior granulocyte transfusions, prior red cell transfusions, infection, age, blood group, diagnosis, sex, pretransfusion platelet count, prior pregnancies, and concurrent antineoplastic drugs. This study identified major clinical factors that significantly influenced CI and were major causes of refractoriness to pooled platelet transfusions.
Similar articles
-
Factors influencing 20-hour increments after platelet transfusion.Transfusion. 1991 Jun;31(5):392-6. doi: 10.1046/j.1537-2995.1991.31591263191.x. Transfusion. 1991. PMID: 2048176
-
The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.Semin Oncol. 1993 Oct;20(5 Suppl 6):102-9. Semin Oncol. 1993. PMID: 8211211 Review.
-
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.Blood. 2005 May 15;105(10):4106-14. doi: 10.1182/blood-2003-08-2724. Epub 2005 Feb 3. Blood. 2005. PMID: 15692069 Free PMC article. Clinical Trial.
-
Platelet transfusions: the problem of refractoriness.Blood Rev. 1990 Mar;4(1):16-24. doi: 10.1016/0268-960x(90)90013-i. Blood Rev. 1990. PMID: 2182145 Review.
-
The definition of refractoriness to platelet transfusions.Transfus Med. 1992 Mar;2(1):35-41. doi: 10.1111/j.1365-3148.1992.tb00132.x. Transfus Med. 1992. PMID: 1308461
Cited by
-
Factors Influencing Corrected Count Increment After Platelet Transfusion in Thrombocytopenic Patients.Cureus. 2023 Sep 28;15(9):e46161. doi: 10.7759/cureus.46161. eCollection 2023 Sep. Cureus. 2023. PMID: 37908942 Free PMC article.
-
A meta-analysis of risk factors associated with platelet transfusion refractoriness.Int J Hematol. 2023 Jun;117(6):863-875. doi: 10.1007/s12185-023-03557-3. Epub 2023 Mar 1. Int J Hematol. 2023. PMID: 36856992
-
Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis.Front Med (Lausanne). 2022 May 6;9:873500. doi: 10.3389/fmed.2022.873500. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35602482 Free PMC article.
-
The relevance of a bank with genotyped platelets donors.Hematol Transfus Cell Ther. 2022 Oct-Dec;44(4):465-471. doi: 10.1016/j.htct.2021.03.006. Epub 2021 May 18. Hematol Transfus Cell Ther. 2022. PMID: 34083156 Free PMC article.
-
Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion.Transfus Med Rev. 2020 Oct;34(4):242-249. doi: 10.1016/j.tmrv.2020.09.002. Epub 2020 Sep 17. Transfus Med Rev. 2020. PMID: 33129606 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
